(0.16%) 5 222.68 points
(0.32%) 39 513 points
(-0.03%) 16 341 points
(-1.34%) $78.20
(-2.13%) $2.25
(1.14%) $2 366.90
(0.11%) $28.40
(1.48%) $1 005.50
(0.11%) $0.928
(-0.30%) $10.83
(-0.01%) $0.798
(-0.42%) $92.15
Live Chart Being Loaded With Signals
Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system...
Stats | |
---|---|
Today's Volume | 268 578 |
Average Volume | 128 001 |
Market Cap | 48.04M |
EPS | $0 ( 2024-05-09 ) |
Next earnings date | ( $0 ) 2024-08-05 |
Last Dividend | $0.0900 ( 2014-08-29 ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.690 |
ATR14 | $0.0110 (0.87%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-04 | Yonehiro Grant | Buy | 235 000 | Stock Option (Right to Buy) |
2024-03-04 | Perez Edith A. | Buy | 235 000 | Stock Option (Right to Buy) |
2024-03-04 | Schatzman Randall C | Buy | 654 000 | Stock Option (Right to Buy) |
2024-03-04 | Quinn William P. | Buy | 235 000 | Stock Option (Right to Buy) |
2023-12-31 | Yonehiro Grant | Buy | 0 |
INSIDER POWER |
---|
73.36 |
Last 93 transactions |
Buy: 5 349 325 | Sell: 1 125 168 |
Volume Correlation
Bolt Biotherapeutics, Correlation
10 Most Positive Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Bolt Biotherapeutics, Correlation - Currency/Commodity
Bolt Biotherapeutics, Financials
Annual | 2023 |
Revenue: | $7.88M |
Gross Profit: | $5.99M (76.08 %) |
EPS: | $-1.830 |
FY | 2023 |
Revenue: | $7.88M |
Gross Profit: | $5.99M (76.08 %) |
EPS: | $-1.830 |
FY | 2022 |
Revenue: | $5.73M |
Gross Profit: | $838 000 (14.63 %) |
EPS: | $-2.30 |
FY | 2021 |
Revenue: | $0.00 |
Gross Profit: | $0.00 (0.00 %) |
EPS: | $-2.97 |
Financial Reports:
No articles found.
Bolt Biotherapeutics, Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $0.0500 | 2012-03-06 |
Last Dividend | $0.0900 | 2014-08-29 |
Next Dividend | $0 | N/A |
Payout Date | 2014-10-02 | |
Next Payout Date | N/A | |
# dividends | 11 | -- |
Total Paid Out | $0.830 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 1.61 | -- |
Div. Sustainability Score | 0.326 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0 | -- |
Year | Amount | Yield |
---|---|---|
2012 | $0 | 0.00% |
2013 | $0 | 0.00% |
2014 | $0 | 0.00% |
2015 | $0 | 0.00% |
2016 | $0 | 0.00% |
2017 | $0 | 0.00% |
2018 | $0 | 0.00% |
2019 | $0 | 0.00% |
2020 | $0 | 0.00% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
QYLD | Dividend Royal | 2023-11-20 | Monthly | 11 | 7.50% | 8.50 |
PSEC | Dividend Royal | 2023-12-26 | Monthly | 21 | 7.04% | 8.50 |
GAIN | Dividend Royal | 2023-12-04 | Monthly | 20 | 8.19% | 8.50 |
GLDI | Dividend Royal | 2023-11-20 | Monthly | 12 | 7.15% | 8.50 |
OXLC | Dividend Royal | 2023-12-14 | Monthly | 14 | 10.00% | 8.50 |
OXSQ | Dividend Royal | 2023-12-14 | Monthly | 21 | 9.10% | 8.50 |
SLVO | Dividend Royal | 2023-11-20 | Monthly | 12 | 10.77% | 8.50 |
HRZN | Dividend King | 2023-12-18 | Monthly | 15 | 6.60% | 8.45 |
USOI | Dividend Royal | 2023-11-20 | Monthly | 8 | 16.70% | 8.28 |
PFLT | Dividend King | 2023-11-15 | Monthly | 14 | 6.50% | 8.27 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -8.60 | 1.500 | -10.00 | -10.00 | [0 - 0.5] |
returnOnAssetsTTM | -0.424 | 1.200 | -10.00 | -10.00 | [0 - 0.3] |
returnOnEquityTTM | -0.501 | 1.500 | -6.68 | -10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 5.16 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 5.06 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 0.528 | 1.500 | 8.18 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.127 | -1.500 | 7.89 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 53.10 | 1.000 | 10.00 | 10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | -1.832 | 2.00 | -0.611 | -1.222 | [0 - 30] |
freeCashFlowPerShareTTM | -1.838 | 2.00 | -0.919 | -1.838 | [0 - 20] |
debtEquityRatioTTM | 0.179 | -1.500 | 9.28 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.577 | 1.000 | 3.72 | 3.72 | [0.2 - 0.8] |
operatingProfitMarginTTM | -9.67 | 1.000 | -10.00 | -10.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -3.44 | 1.000 | -10.00 | -10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.0493 | 0.800 | -3.00 | -2.40 | [0.5 - 2] |
Total Score | 0.326 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -0.706 | 1.000 | -0.172 | 0 | [1 - 100] |
returnOnEquityTTM | -0.501 | 2.50 | -4.29 | -10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -1.838 | 2.00 | -0.613 | -1.838 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -1.832 | 2.00 | -0.611 | -1.222 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0.00526 | 1.500 | -3.30 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -8.83 | 1.000 | -10.00 | 0 | [0.1 - 0.5] |
Total Score | -2.76 |
Bolt Biotherapeutics,
Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors; BDC-2034, a carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers; and BDC-3042, a Dectin-2 agonist antibody program developed to repolarize critical cells in the tumor microenvironment by targeting cell-surface receptors on macrophages. It is also developing programmed cell death-ligand 1 program for tumors that are nonresponsive to immune checkpoint blockade. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood city, California.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators